ro 8-0576 has been researched along with 5-hydroxytryptophan in 2 studies
| Studies (ro 8-0576) | Trials (ro 8-0576) | Recent Studies (post-2010) (ro 8-0576) | Studies (5-hydroxytryptophan) | Trials (5-hydroxytryptophan) | Recent Studies (post-2010) (5-hydroxytryptophan) |
|---|---|---|---|---|---|
| 214 | 63 | 67 | 4,177 | 157 | 298 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battegay, R; Gastpar, M; Zmilacher, K | 1 |
| Blau, N; Dill, P; Somerville, A; Thöny, B; Wagner, M; Weber, P | 1 |
2 other study(ies) available for ro 8-0576 and 5-hydroxytryptophan
| Article | Year |
|---|---|
L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression.
Topics: 5-Hydroxytryptophan; Adult; Aged; Benserazide; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Psychological Tests; Retrospective Studies | 1988 |
Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency.
Topics: 5-Hydroxytryptophan; Alcohol Oxidoreductases; Behavior; Benserazide; Consanguinity; Developmental Disabilities; Dopamine Agents; Drug Combinations; Eye Movements; Female; Humans; Infant; Levodopa; Movement Disorders; Muscle Hypotonia; Nervous System Diseases; Neurotransmitter Agents; Phenylketonurias; Treatment Outcome | 2012 |